Tonapofylline

Drug Profile

Tonapofylline

Alternative Names: Adentri; BG-9928

Latest Information Update: 16 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CV Therapeutics
  • Developer Biogen Idec
  • Class Heart failure therapies; Small molecules; Xanthines
  • Mechanism of Action Adenosine A1 receptor antagonists; Adenosine A2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute heart failure; Chronic heart failure

Most Recent Events

  • 17 Apr 2009 CV Therapeutics has been acquired and merged into Gilead Sciences
  • 22 Aug 2008 Phase-III clinical trials in Acute heart failure in World (IV)
  • 16 Aug 2007 Final results from a phase II clinical trial in Chronic heart failure added to the Heart Failure therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top